Last reviewed · How we verify
Cleviprex®
Cleviprex is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing blood pressure.
Cleviprex is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing blood pressure. Used for Acute hypertension (perioperative and postoperative settings).
At a glance
| Generic name | Cleviprex® |
|---|---|
| Also known as | Clevidipine Butyrate Injectable Emulsion |
| Sponsor | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Cleviprex works by blocking calcium influx into vascular smooth muscle cells through L-type calcium channels, which prevents smooth muscle contraction and leads to vasodilation of arteries. This results in rapid reduction of blood pressure. The drug is highly selective for vascular tissue and has a rapid onset and offset of action due to its ester structure, which is quickly metabolized by red blood cell esterases.
Approved indications
- Acute hypertension (perioperative and postoperative settings)
Common side effects
- Headache
- Nausea
- Hypotension
- Reflex tachycardia
Key clinical trials
- a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency (PHASE3)
- A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency (PHASE3)
- Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) (PHASE4)
- A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cleviprex® CI brief — competitive landscape report
- Cleviprex® updates RSS · CI watch RSS
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. portfolio CI